Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5074-5081

  Rochat, Bertrand ^a   Pascual, Andres ^a   Pesse, Benoît ^a   Lamoth, Frédéric ^a   Sanglard, Dominique ^a   Decosterd, Laurent A ^a   Bille, Jacques ^a   Marchetti, Oscar ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; CYCLOSPORIN; FLUCONAZOLE; IMIPENEM; INDINAVIR; ITRACONAZOLE; MEROPENEM; METRONIDAZOLE; NELFINAVIR; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TACROLIMUS; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ADOLESCENT; AGED; ARTICLE; BIOASSAY; CANDIDA ALBICANS; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GENE DELETION; HUMAN; INFECTION PREVENTION; MALE; MYCOSIS; PRECIPITATION; PRIORITY JOURNAL; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADMINISTRATION, ORAL; BIOLOGICAL ASSAY; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 78649649990     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00022-10     Document Type: Article

References (38)

1. Andes, D., A. Pascual, and O. Marchetti. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
2. Brüggemann, R. J., D. J. Touw, R. E. Aarnoutse, P. E. Verweij, and D. M. Burger. 2009. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob. Agents Chemother. 53:303-305.
3. Bryant, A. M., D. Slain, A. Cumpston, and M. Craig. 2009. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A1-590.
4. Chhun, S., E. Rey, A. Tran, O. Lortholary, G. Pons, and V. Jullien. 2007. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852:223-228.
5. Colombo, S., A. Beguin, A. Telenti, J. Biollaz, T. Buclin, B. Rochat, and L. A. Decosterd. 2005. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 819:259-276.
6. Conte, J. E., Jr., J. A. Golden, G. Krishna, M. McIver, E. Little, and E. Zurlinden. 2009. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 53:703-707.
7. Cornely, O. A., J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann, T. J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y. T. Goh, M. Petrini, C. Hardalo, R. Suresh, and D. Angulo-Gonzalez. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
8. Courtney, R., A. Sansone, W. Smith, T. Marbury, P. Statkevich, M. Martinho, M. Laughlin, and S. Swan. 2005. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 45:185-192.
9. Courtney, R., D. Wexler, E. Radwanski, J. Lim, and M. Laughlin. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222.
10. Cunliffe, J. M., C. F. Noren, R. N. Hayes, R. P. Clement, and J. X. Shen. 2009. A high-throughput LC-MS/MS method for the quantitation of posaconazole in human plasma: implementing fused core silica liquid chromatography. J. Pharm. Biomed. Anal. 50:46-52.
11. Ezzet, F., D. Wexler, R. Courtney, G. Krishna, J. Lim, and M. Laughlin. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220.
12. Food and Drug Administration. 2001. Guidance for industry: bioanalytical method validation. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf.
13. Food and Drug Administration. 2009. 4 January 2010, accession date. Posaconazole. FDA briefing document. Food and Drug Administration, Rockville, MD. http://www.aapsj.org/abstracts/AM-2007/AAPS2007-000993.PDF.
14. Hope, W. W., and G. L. Drusano. 2009. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin. Microbiol. Infect. 15:602-612.
15. Kahle, K., P. Langmann, D. Schirmer, U. Lenker, D. Keller, A. Helle, H. Klinker, and W. J. Heinz. 2009. Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob. Agents Chemother. 53:3140-3142.
16. Kim, H., C. C. Lin, M. Laughlin, R. Lovey, A. Saksena, L. Heimark, and A. A. Nomeir. 2000. Chiral high-performance liquid chromatographic analysis of antifungal SCH 56592 and evaluation of its chiral inversion in animals and humans. Chirality 12:590-597.
17. Kim, H., P. Kumari, C. C. Lin, and A. A. Nomeir. 2002. Simultaneous high-performance liquid chromatographic determination of SCH 59884 (phosphate ester prodrug of SCH 56592), SCH 207962 and SCH 56592 in dog plasma. J. Pharm. Biomed. Anal. 27:295-303.
18. Kohl, V., C. Müller, O. A. Cornely, K. Abduljalil, U. Fuhr, J. J. Vehreschild, C. Scheid, M. Hallek, and M. J. Rüping. 2010. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob. Agents Chemother. 54:207-212.
19. Krishna, G., M. Martinho, P. Chandrasekar, A. J. Ullmann, and H. Patino. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636. (Pubitemid 350234311)
20. Krishna, G., A. Moton, L. Ma, M. M. Medlock, and J. McLeod. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966.
21. Lebeaux, D., F. Lanternier, C. Elie, F. Suarez, A. Buzyn, J. P. Viard, M. E. Bougnoux, M. Lecuit, V. Jullien, and O. Lortholary. 2009. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob. Agents Chemother. 53:5224-5229.
22. Leventakos, K., R. E. Lewis, I. I. Raad, and D. P. Kontoyiannis. 2009. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-1054.
23. Lin, L. I. 1989. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255-268.
24. Marchetti, O., P. A. Majcherczyk, M. P. Glauser, J. Bille, P. Moreillon, and D. Sanglard. 2001. Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles. Antimicrob. Agents Chemother. 45:696-700.
25. Muller, C., M. Arndt, C. Queckenberg, O. A. Cornely, and M. Theisohn. 2006. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 49(Suppl. 1):17-22.
26. Nagappan, V., and S. Deresinski. 2007. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin. Infect. Dis. 45:1610-1617.
27. Naidong, W., H. Bu, Y. L. Chen, W. Z. Shou, X. Jiang, and T. D. Halls. 2002. Simultaneous development of six LC-MS-MS methods for the determination of multiple analytes in human plasma. J. Pharm. Biomed. Anal. 28:1115-1126.
28. Nomeir, A. A., P. Kumari, M. J. Hilbert, S. Gupta, D. Loebenberg, A. Cacciapuoti, R. Hare, G. H. Miller, C. C. Lin, and M. N. Cayen. 2000. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob. Agents Chemother. 44:727-731.
29. Pascual, A., V. Nieth, T. Calandra, J. Bille, S. Bolay, L. A. Decosterd, T. Buclin, P. A. Majcherczyk, D. Sanglard, and O. Marchetti. 2007. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob. Agents Chemother. 51:137-143.
30. Sanglard, D., F. Ischer, O. Marchetti, J. Entenza, and J. Bille. 2003. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48:959-976.
31. Sansone-Parsons, A., G. Krishna, J. Simon, P. Soni, B. Kantesaria, J. Herron, and R. Stoltz. 2007. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 51:495-502.
32. Shah, V. P., K. K. Midha, J. W. Findlay, H. M. Hill, J. D. Hulse, I. J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, and A. Yacobi. 2000. Bioanalytical method validation - a revisit with a decade of progress. Pharm. Res. 17:1551-1557.
33. Shen, J. X., G. Krishna, and R. N. Hayes. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 43:228-236.
34. Thompson, G. R., III, M. G. Rinaldi, G. Pennick, S. A. Dorsey, T. F. Patterson, and J. S. Lewis II. 2009. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob. Agents Chemother. 53:2223-2224.
35. Ullmann, A. J., J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston, S. R. Tarantolo, H. Greinix, W. Morais de Azevedo, V. Reddy, N. Boparai, L. Pedicone, H. Patino, and S. Durrant. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
36. Ullmann, A. J., O. A. Cornely, A. Burchardt, R. Hachem, D. P. Kontoyiannis, K. Topelt, R. Courtney, D. Wexler, G. Krishna, M. Martinho, G. Corcoran, and I. Raad. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666.
37. Vogeser, M., C. Rieger, H. Ostermann, and U. Spöhrer. 2009. A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry. Clin. Chem. Lab. Med. 47:579-584.
38. Walsh, T. J., I. Raad, T. F. Patterson, P. Chandrasekar, G. R. Donowitz, R. Graybill, R. E. Greene, R. Hachem, S. Hadley, R. Herbrecht, A. Langston, A. Louie, P. Ribaud, B. H. Segal, D. A. Stevens, J. A. van Burik, C. S. White, G. Corcoran, J. Gogate, G. Krishna, L. Pedicone, C. Hardalo, and J. R. Perfect. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.